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ABSTRACT
Objective: To study maternal and neonatal effects of combination nucleoside analog therapy ad-
ministered to human immunodeficiency virus (HIV)-infected pregnant women for maternal indi-
cations.
Methods:A multicenter, prospective observational study was undertaken at six perinatal centers
in the United States and Canada that supported regional referral programs for the treatment of
HIV-infected pregnant women. Demographic, laboratory, and pregnancy outcome data were col-
lected for 39 women whose antiretroviral treatment regimens were expanded to include more than
one nucleoside analog for maternal indications. The 40 newborns were monitored at pediatric
referral centers through at least three months of age to ascertain their HIV infection status.
Results: For all 39 women, zidovudine (ZDV) therapy was instituted at 13.4 8.2 weeks, with
a second agent (lamivudine [3TC] in 85% of cases) being added at a mean gestational age of 17.6
weeks. Duration of therapy with two agents was 20.6+ 10.4 weeks overall, with no women stopping
medications because of side effects or toxicity. No significant changes in maternal laboratory values
were seen, except for an increase in mean corpuscular volume, over the course of pregnancy. No
clinically significant adverse neonatal outcomes were noted, with all but the three preterm new-
borns leaving hospital with their mothers. Neonatal anemia (hematocrit < 50%) was seen in 62% of
newborns, with no children needing transfusion; mild elevations of liver function tests, primarily
aspartate aminotransferase, were noted in 58% of newborns tested, though none were clinically
jaundiced. Overall rate of neonatal HIV infection was 2.5% (95% confidence interval: 0.1-13.2%).
Conclusion: Combination antiretroviral therapy during pregnancy with two nucleoside analogs
was well-tolerated by mothers and newborns, with no significant short-term toxicities or side effects
noted. Surveillance ofexposed newborns’ hematologic and liver function appears warranted. Infect.
Dis. Obstet. Gynecol. 6:237-243, 1998. (C) 1999 Wiley-Liss, Inc.
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ecent advances in the treatment of adults in-
fected with the human immunodeficiency vi-
rus (HIV) have established combination antiretro-
viral therapy as the current standard for treatment
of these individuals. The most recent guidelines
proposed by both the US Department of Health
and Human Services and the International AIDS
Society reinforce this approach, 1,e emphasizing that
treatment decisions include evaluation of an indi-
vidual patient’s immune status via HIV-RNA and
CD4+ cell analyses, but stressing the u’se of at least
two, and ideally three, antiretroviral medications at
the initiation of therapy. The ultimate goal of all
HIV therapeutic regimens is designed to be the
suppression of HIV-RNA below detectable levels,
which has been shown to be directly related to the
risk of disease progression.
3
With HIV infection, as with other medical con-
ditions, a coexisting pregnancy presents unique
concerns regarding appropriateness and safely of
treatment options, even those that have clearly
been of benefit for nonpregnant adults. A regimen
of maternal and neonatal therapy with zidovudine
(ZDV) in HIV-exposed pregnancies has been
shown in a large multicenter trial to significantly
decrease the risk of vertical HIV transmission by
nearly 70%, from 25% to 8%.4 This therapy was
well-tolerated by the women participating in the
trial, with neonatal effects appearing to be limited
to mild transient anemia.4 Subsequent single-
center or regional reports have demonstrated simi-
larly encouraging results regarding interruption of
vertical HIV transmission with the use of all or only
some of the treatment components of the larger
trial’s ZDV protocol,s-s These positive results have
led the United States Public Health Service
(USPHS) to recommend offering HIV counseling
and testing to all pregnant women, so that women
diagnosed as HIV-infected can be offered treat-
ment that would both decrease the risk of neonatal
infection and delay the progression of maternal dis-
ease.9, lo
The current adult guidelines recognize that the
trials to interrupt perinatal HIV transmission, using
ZDV alone for antepartum/intrapartum/neonatal
therapy, stand in contrast to evolving standards for
adult HIV therapy. The most recent USPHS rec-
ommendations for the treatment of HIV-infected
pregnant women, in fact, now state that "therapies
of known benefit to women should not be withheld
during pregnancy unless.., adverse effects out-
weigh the benefit to the woman, ’’1 an approach
supported by other experts in the obstetric litera-
ture.z However, the authors of these guidelines
acknowledge a paucity of human neonatal side-
effect data regarding in utero exposure to antiret-
roviral agents other than ZDV.
Data regarding the safety of antiretroviral agents
other than ZDV during pregnancy, to date, are lim-
ited to abstract presentations or small series evalu-
ating late-pregnancy treatment.3-s Many clini-
cians providing care to HIV-infected women dur-
ing pregnancy have used medications other than
ZDV for maternal indications, encouraged by any
lack of association reported between congenital
malformations and maternal treatment with other
nucleoside analogs, specifically ZDV and acyclo-
vir.4’16,7 Therefore, we sought to report on our
centers’ preliminary, cumulative experience with
combination antiretroviral regimens for HIV-
infected mothers, for whom treatment had been
designed with the intent of maximal viral-
suppressive benefit for both the women and their
newborns. While our series is not intended to sup-
plant larger registry reports, we felt it important to
combine our early treatment experiences in light of
the recommendations for expanded maternal
therapy outlined in the new perinatal HIV treat-
ment guidelines,
al While limited in size, we in-
tended our series to begin to fill the gaps that cur-
rently exist in counseling pregnant patients in need
of appropriately aggressive antiretroviral therapies.
METHODS
The study population consisted of all HIV-infected
women referred for counseling and prenatal care at
the referring centers. From 1995 through Decem-
ber 1997, women at these centers who were either
newly diagnosed with HIV infection or known to
be infected but previously untreated were offered
combination antiretroviral therapy with zidovudine
(AZT) and an additional nucleoside analog. Each
woman underwent individual counseling regarding
pregnancy options and HIV treatment options.
The results of the multicenter AZT trial (AIDS
Clinical Trial Group Protocol #076)4 were dis-
cussed in detail, and recommendations for the use
of at least AZT to decrease perinatal HIV transmis-
sion were outlined.1 However, the clinicians at
these centers also discussed the use of additional
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antiretroviral agents to favorably impact on mater-
nal viral load and disease progression and possibly
to augment the prophylactic impact on the new-
born. The lack of neonatal exposure and safely data
was discussed with all women in the context of
risk-benefit decisions.
As the observation period progressed, all centers
encountered women who had been diagnosed prior
to the index pregnancies and had been on combi-
nation regimens preconceptionally. After discus-
sions with these women, any successful HIV treat-
ment regimens were continued in the absence of
maternal disease progression.
At the beginning of the study period, women
na’fve to antiretroviral therapy with favorable lym-
phocyte subset profiles (CD4+ subset > 500 cells/
mm3) were placed on AZT alone in accordance
with Centers for Disease Control and Prevention
(CDC)/USPHS guidelines,
1 with a second agent
added if predetermined parameters (CD4+ subset
or HIV-RNA levels) deteriorated. Not all centers
used viral RNA levels uniformly throughout the
observation period. As guidelines became estab-
lished in nonpregnant adult populations, drug-
na’ive women meeting adult criteria for treatment
outside of pregnancy were begun concomitantly on
two agents at 12-14 weeks of gestation.
Hematologic, serum chemistry, and lymphocyte
subset values were monitored through the wom-
en’s pregnancies, with complete blood counts per-
formed on all and liver function testing performed
on most newborns. Complete nursery examinations
were performed on all newborns by the centers’
pediatric staffs, and delivery statistics were col-
lected on all exposed newborns. Neonatal virologic
status was sought on all exposed infants. All chil-
dren were treated with oral ZDV in accordance
with established pediatric guidelines.
Continuous data were compared by both paired
and unpaired Student t-tests, with noncontinuous
paired data analyzed with Wilcoxon signed rank
tests. Statistically significant differences between
comparison groups were defined at a level of P <
0.05, with 95% confidence levels assigned where
appropriate.
RESULTS
The investigators at the six contributing centers
monitored 39 HIV-infected women, each of whom
TABLE I. Maternal antiretroviral therapy
Mean Median
(+SDa) (range)
Gestational age ZDV started (weeks)
Gestational age 2nd agent started
(weeks)
If patient symptomatic (n 5)
If patient asymptomatic (n 34)
Duration of combined therapy (weeks)
13.4 + 8.2 12 (6-36)
17.6 _+ 10.7 14 (6-37)
8.0 + 4.0
18.6 + 10.3
20.6 _+ 10.4 22 (3-34)
aSD, standard deviation.
was treated with two nucleoside analogs during
their pregnancies, and who delivered 40 live new-
borns (one set of twins) among them. These
women, with a mean age of 27.4 _+ 5.2 years, had
been diagnosed with HIV infection for a median of
two years (range: 0-11 years), with 14 (35.9%) di-
agnosed with the index pregnancy, and 29 (74.4%)
diagnosed for less than five years. Only five (13%)
had had symptomatic sequelae of their HIV infec-
tion; in two of these women, pneumocystis carinii
pneumonia had been the presenting illness that
prompted diagnosis prior to pregnancy. The major-
ity ofwomen (69%) identified heterosexual contact
alone as their infection risk, with 28% reporting
prior or ongoing drug use, and one woman (3%)
having acquired her infection through past transfu-
sion of blood products.
For all women, ZDV therapy (200 mg, orally,
three times a day) was instituted at 12-14 weeks of
gestation (or at the first visit, if later) if antiretro-
viral treatment was not continuing from the
prepregnancy period. As seen in Table 1, ZDV was
begun soon after completion of the first trimester
in the majority of women; only five women were
placed on ZDV after 20 weeks of gestation, all of
whom presented late for care and were diagnosed
as HIV-infected during the index pregnancy.
Combination nucleoside analog therapy was in-
stituted later in pregnancy on average, though as
the study period progressed, more women either
entered pregnancy already on two agents or were
concurrently placed on two agents initially at the
prenatal center. Overall, 12 women (30.8%) were
already on two nucleoside analogs at the time of
presenting for prenatal care, 13 (33.3%) were
placed on two agents upon entry to care, with the
remaining 14 (35.9%) placed on a second agent
some time in the second or third trimester, either
for progressive decreases in CD4+ cell counts or
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TABLE 2. Maternal laboratory values (n 39)
At entry At delivery
WBC (103/L) 5.8 + 1.6 7.5 +/- 2.6*
Hemoglobin (g/dL) 11.5 + I. 11.4 +/- 1.5
MCV (fL) 93 +/- 10.5 102.3 +/- 11.5"
Platelets (103/L) 220 +/- 61 220 + 58
AST (IU/L) 26.8 +/- 12.7 28.7 +/- 13.7
ALT (IU/L) 23.7 +/- 15.7 23.9 +/- 17.3
CD4 (median cells/
mm3, range) 274 (30-932) 340 (45-81 I)**
AII means + standard deviation except where indicated.
*P < 0.001 by paired t-tests.
**P 0.06 by Wilcoxon signed rank test.
increases in HIV-RNA levels, depending on the
center. The majority ofwomen were given lamivu-
dine (3TC) as the second nucleoside analog (33/39;
84.6%), with four women treated with didanosine
(ddI), and two with zalcitabine (ddC). For the pur-
poses of analysis, the presence of a second nucleo-
side analog during the pregnancy was not stratified
by agent used, due to the small size of the ddI and
ddC groups.
Table 2 shows the maternal laboratory values
followed during the women’s pregnancies. There
were increases noted in the white blood cell (WBC)
counts and the mean corpuscular volumes (MCV)
in women when paired analyses comparing entry
values to delivery values were performed. No sig-
nificant increases were noted in other hematologic
values, liver function tests, or median CD4+ cell
counts. No women discontinued their therapy dur-
ing pregnancy as a result of either laboratory tox-
icity or unacceptable side effects.
Table 3 describes delivery data for the 40 new-
borns. As shown, the majority of pregnancies were
delivered at 36 weeks of gestation or more. The
three women who delivered at earlier gestational
ages (at 32, 33, and 35 weeks) did so for non-HIV-
related complications (one for chronic hypertension
and fetal distress, and two for refractory preterm
labor without clinical chorioamnionitis). Nearly
three fourths of the women delivered vaginally
(71.8%; 95% confidence interval [CI] 55.1-85%);
the 11 women who delivered via cesarean delivery
had surgery performed for obstetric indications
(breech presentation, arrest of dilatation, and active
genital herpes) rather than maternal HIV-related
concerns.
Neonatal outcome data from the 39 pregnancies
are summarized in Table 4. No clinical d7smor-
TABLE 3. Delivery data
Gestational age at delivery (weeks)
Delivery ->36 weeks
Birthweight (grams)
Birthweight for all ->36 weeks (n 37)
Vaginal delivery
38.2 + 2.
(median 38 wk)
36 (92.3%)
2979 + 667
3068 + 597
28 (71.8%)
TABLE 4. Newborn laboratory values (n 40)
WBC (103/L) 13.2 + 4.7
Hemoglobin (g/dL) 15.6 + 3.0
Hematocrit (%) 47 + 8.9
Platelets (103/L) 266 +/- 97
AST (IU/L)[n 24] 46 + 20
ALT (IU/L)[n 24] 15 + 10
Anemia (Hct <50%) 25 (62.5%)
Mean hematocrit for anemic newborns (%) 41.2 + 5.5
Mean hematocrit for nonanemic newborns (%) 55.2 + 6.2
Elevated ALT or AST (>35 IU/L) 14/24 (58.3%)
ALT or AST >1.5 x upper limit
of normal range 6/24 (25%)
phology was identified in any of these children,
and, despite a rate of neonatal anemia (defined as
hematocrit < 50%) of 62% (95% CI 45.8-77.3%),
none of the newborns required blood transfusion.
No clinically significant laboratory abnormalities
were identified in these children, though it is no-
table that of the 24 newborns with liver function
tests available, 14 (58.3%) had elevations of either
alanine aminotransferase (ALT) or aspartate ami-
notransferase (AST), defined as a value higher than
35 IU/L. When elevated neonatal liver function
tests were defined as ALT or AST greater than 1.5
times the upper limit of normal, however, only six
of 24 newborns (25%) met those criteria. None of
these children were clinically jaundiced or required
phototherapy, however, and all but the three pre-
term newborns were discharged home with their
mothers.
The nature of this report precludes conclusions
about the effectiveness of double-nucleoside
therapy during pregnancy for interrupting vertical
HIV transmission, and maternal HIV-RNA levels
were not followed consistently enough among the
centers to remark on trends or effects. However,
virologic status through at least three months of age
is available on all the newborns in this study, with
only one diagnosed as HIV-infected by both poly-
merase chain reaction testing of HIV-RNA and by
viral culture, giving a vertical transmission rate in
this series of 2.5% (95% CI 0.1-13.2%). Of note
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is the fact that this child’s mother had a docu-
mented acute HIV seroconversion during the index
pregnancy.
COMMENTS
Recent guidelines for the treatment of HIV-
infected pregnant women have brought antiretro-
viral recommendations for this population into con-
cordance with those for other adult and adolescent
populations, e,ll Treatment regimens, therefore,
should be designed to maximize benefit for the
mother, with the presumption that optimal mater-
nal viral suppression will also contribute to lower-
ing the risk of vertical HIV transmission, ls-z
The integration of ZDV therapy into antepar-
tum and intrapartum management of HIV-infected
women has contributed significantly to the docu-
mented decline in the incidence of perinatally-
acquired HIV infection in the United States.zz Be-
cause perinatal transmission of HIV now accounts
for virtually all new HIV infections in children,z3
maximizing the effectiveness of therapies designed
to interrupt vertical transmission is of critical im-
portance.
Through collaborative compilation of data from
six perinatal centers, we have been able to present
a preliminary experience with the use of combina-
tion nucleoside analog therapy during pregnancy.
These outcomes predate the inclusion of protease
inhibitors in most adult combination regimens and
reflect the intent of the investigators to augment
maternal therapy by using additional medica-
tions from a class for which neonatal exposure and
safety profiles had at least been previously de-
scribed.4,16,7 For the most part, lamivudine was
the second agent of choice, since its acceptability
to patients in terms of dosing and side effects had
been well-described in other adult groups,z4,zs In
addition, the transplacental .passage of lamivudine
in laboratory models using human placentas has
been shown to result in favorable maternal-fetal
compartment ratios,e6 All investigators maintained
ZDV therapy during the women’s pregnancies,
since it is the only agent for which interruption of
vertical HIV transmission has been documented,4
though it was expected that other similar agents in
combination would have at least comparable if not
improved effects on these transmission rates.
Our results demonstrate that combination
nucleoside therapy was well-tolerated by all the
women, with none of them discontinuing treat-
ment for side effects or laboratory toxicities. Nearly
all of the women delivered at term, similar to those
participating in the ACTG-076 trial,4 with maternal
HIV status in our series not related to route of
delivery. There were no clinically significant dif-
ferences in laboratory values monitored in these
women from the time of entry into care through
delivery. While HIV-RNA levels would have been
interesting to monitor, they were not drawn con-
sistently enough across the centers to allow for ap-
propriate data analysis.
These initial data also indicate that combination
nucleoside therapy appeared to be well-tolerated
by the exposed children. Rates of neonatal anemia
were comparable to those in populations of chil-
dren exposed to ZDV alone,4 with no transfusions
required; all other hematologic parameters were
within normal neonatal ranges. It is notable that
elevations of liver function tests were seen in chil-
dren exposed to combination therapy, an effect not
observed in the larger multicenter ZDV-only trial.4
Not all of the children in our series were monitored
longitudinally, though none were clinically jaun-
diced at birth, and it appeared to be the serum AST
that was elevated selectively, with a mean value
approximately 25% above the upper normal limit of
35 IU/L for this test. In addition, if significant
transaminase elevations are considered to be those
greater than 1.5 times the upper limit of normal,
only 25% of exposed newborns would have met
those criteria.
The small sample size of this series precludes
substantial comment on the value of combination
therapy to augment the impact of ZDV alone in
interrupting vertical HIV transmission.4 In contrast
to the initial ZDV treatment trial, women in this
series had lower median CD4+ cell counts at entry
and were not excluded from therapy for symptom-
atic status. Still, our overall rate of neonatal HIV
infection was only 2.5%, which is at least compa-
rable to the 5-8% rates reported in other random-
ized and nonrandomized series of treatment with
ZDV alone.4,s Definitive conclusions about the im-
pact of combination therapy on vertical transmis-
sion of HIV, however, are beyond the scope of this
preliminary report.
Our combined experience does provide early
objective support for the use of combination
nucleoside analog therapy for the treatment of
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HIV-infected women during pregnancy when regi-
mens are intended to maximize antiretroviral ben-
efit for the women. An additional side-benefit in
further decreasing the risk of vertical HIV trans-
mission beyond that demonstrated for ZDV alone
may ultimately be proven. However, this series
does describe the first maternal and neonatal safety
profiles for combination HIV therapy administered
through the major portion of pregnancy in HIV-
infected women in accordance with recently re-
vised CDC guidelines.
11 Hematologic and liver
function profiles in exposed newborns appear to
warrant careful surveillance, though no significant
short-term neonatal morbidities or toxicities were
identified. Even as the nature of treatment of
chronic HIV-related illness continues to progress,
these early results should greatly assist in the coun-
seling and medical management of HIV-infected
pregnant women until larger registry reports be-
come available.
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